%0 Journal Article
%T 小分子EGFR-TKIs在非小细胞肺癌治疗中的研究进展<br>Research Advances of Small Molecule EGFR-TKIs in NSCLC
%A 胡亚南
%J Pharmacy Information
%P 1-9
%@ 2160-4452
%D 2024
%I Hans Publishing
%R 10.12677/PI.2024.131001
%X <span style=\"font-size:14px;\">小分子表皮生长因子受体酪氨酸激酶抑制剂(epithelial growth factor receptor tyrosine kinase in-hibitor, EGFR-TKI)在治疗伴有EGFR突变的非小细胞肺癌(non-small cell lung cancer, NSCLC)中获得了巨大的临床收益。但患者经过一段时间EGFR-TKIs治疗，不可避免的出现获得性耐药。本文主要对小分子EGFR-TKIs在NSCLC治疗中的研究进展及进行综述，为该类药物的临床使用及未来的研究方向提供参考。</span><br />
<span style=\"font-size:14px;\">Small molecule epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has achieved great clinical benefits in the treatment of non-small cell lung cancer (NSCLC) with EGFR mutation. However, after a period of EGFR-TKIs treatment, patients will inevitably acquire drug resistance. Thereview summarizes the research progress of EGFR-TKIs in the treatment of NSCLC which will provide reference for the clinical application and the future of EGFR-TKIs discovery.</span>
%K 表皮生长因子受体，酪氨酸激酶抑制剂，非小细胞肺癌，突变，耐药<br>Epidermal Growth Factor Receptor
%K Tyrosine Kinase Inhibitor
%K Non-Small Cell Lung Cancer
%K Mutation
%K Drug Resistance
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=78914